Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies.

Published on Jul 20, 2021in Quality of Life Research2.773
· DOI :10.1007/S11136-021-02810-8
Kerstin Wohlleber (Heidelberg University), Patrick Heger8
Estimated H-index: 8
(Heidelberg University)
+ 3 AuthorsAndré L. Mihaljevic20
Estimated H-index: 20
(Heidelberg University)
Purpose null Patient-reported outcomes including health-related quality of life (HRQoL) are important oncological outcome measures. The validation of HRQoL instruments for patients with hepatocellular and cholangiocellular carcinoma is lacking. Furthermore, studies comparing different treatment options in respect to HRQoL are sparse. The objective of the systematic review and meta-analysis was, therefore, to identify all available HRQoL tools regarding primary liver cancer, to assess the methodological quality of these HRQoL instruments and to compare surgical, interventional and medical treatments with regard to HRQoL. null Methods null A systematic literature search was conducted in MEDLINE, the Cochrane library, PsycINFO, CINAHL and EMBASE. The methodological quality of all identified HRQoL instruments was performed according to the COnsensus-based Standards for the selection of health status Measurements INstruments (COSMIN) standard. Consequently, the quality of reporting of HRQoL data was assessed. Finally, wherever possible HRQoL data were extracted and quantitative analyses were performed. null Results null A total of 124 studies using 29 different HRQoL instruments were identified. After the methodological assessment, only 10 instruments fulfilled the psychometric criteria and could be included in subsequent analyses. However, quality of reporting of HRQoL data was insufficient, precluding meta-analyses for 9 instruments. null Conclusion null Using a standardized methodological assessment, specific HRQoL instruments are recommended for use in patients with hepatocellular and cholangiocellular carcinoma. HRQoL data of patients undergoing treatment of primary liver cancers are sparse and reporting falls short of published standards. Meaningful comparison of established treatment options with regard to HRQoL was impossible indicating the need for future research.
📖 Papers frequently viewed together
6 Citations
58 Citations
#1Chung Ying Lin (PolyU: Hong Kong Polytechnic University)H-Index: 31
#2Jing-Shiang Hwang (AS: Academia Sinica)H-Index: 32
Last. Jung-Der Wang (NCKU: National Cheng Kung University)H-Index: 72
view all 8 authors...
Background Quality of life (QoL) is important for clinicians to evaluate how cancer survivors judge their sense of well-being, and WHOQOL-BREF may be a good tool for clinical use. However, at least three issues remain unresolved: (1) the psychometric properties of the WHOQOL-BREF for cancer patients are insufficient; (2) the scoring method used for WHOQOL-BREF needs to be clarify; (3) whether different types of cancer patients interpret the WHOQOL-BREF similarly. Methods We recruited 1000 outpat...
33 CitationsSource
#1Andrea Gmür (University of Bern)H-Index: 1
#2Philippe Kolly (University of Bern)H-Index: 9
Last. Jean-François Dufour (University of Bern)H-Index: 65
view all 4 authors...
BACKGROUND AND AIM The Eastern Cooperative Oncology Group Performance Status (ECOG PS) is a strong predictor of survival for patients with hepatocellular carcinoma (HCC), and is used with liver function and tumour burden in the Barcelona Clinic Liver Cancer (BCLC) staging system. This work assesses whether the health-related quality of life (HRQL), measured by the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire, discriminates HCC patients in terms of survival and a...
9 CitationsSource
Purpose With a limited overall survival (OS) of 20 months in patients diagnosed with intermediate stage hepatocellular carcinoma (HCC), the preservation of quality of life (QoL) during transarterial chemoembolization (TACE) procedures remains a primary goal. The aim of our study was to evaluate the change in QoL amongst patients undergoing repetitive TACE and to identify specific risk factors that may predict change in QoL.
9 CitationsSource
#1Ghassan K. Abou-Alfa (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 52
#2Tim Meyer (UCL: University College London)H-Index: 82
Last. Robin Kate Kelley (UCSF: University of California, San Francisco)H-Index: 36
view all 22 authors...
Abstract Background Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellul...
812 CitationsSource
#1Boris Guiu (French Institute of Health and Medical Research)H-Index: 33
#2Jean-Louis JouveH-Index: 17
Last. Mathieu BoulinH-Index: 10
view all 13 authors...
Background & Aims Idarubicin shows high cytotoxicity against hepatocellular carcinoma (HCC) cells, a high hepatic extraction ratio, and high lipophilicity leading to stable emulsions with lipiodol. A dose-escalation phase I trial of idarubicin_lipiodol (without embolisation) was conducted in patients with cirrhotic HCC to estimate the maximum-tolerated dose (MTD) and to assess the safety, efficacy, and pharmacokinetics of the drug, and the health-related quality of life achieved by patients. Met...
4 CitationsSource
#1Qiu-Ming He (Sichuan University)H-Index: 10
#2Jian Jiang (Sichuan University)H-Index: 15
Last. Lin Yang (Sichuan University)H-Index: 9
view all 5 authors...
Abstract Background For cancer patients, health-related quality of life (HRQoL) is as important as other key outcomes, such as overall survival and tumor-free survival. Liver transplantation (LT), resection, and radiofrequency ablation (RFA) are 3 radical therapies for hepatocellular carcinoma (HCC) that result in similar survival. The main objective of this study was to assess and compare long-term HRQoL scores for patients with early-stage (tumor diameter ≤3 cm) HCC after LT, resection, or RFA...
12 CitationsSource
#1Malin Sternby Eilard (University of Gothenburg)H-Index: 5
#2Hannes Hagström (Karolinska University Hospital)H-Index: 22
Last. Magnus Rizell (University of Gothenburg)H-Index: 23
view all 8 authors...
Background & Aims Prognostication in hepatocellular carcinoma (HCC) is demanding. Not only tumour extent and performance status are to be considered, but also liver function, which is often limiting for both survival itself and for treatment possibilities. This study was conducted to assess whether patient-reported questionnaires containing general and liver-specific questions could improve prognostication of survival. Methods 185 patients with hepatocellular carcinoma in Norway and Sweden were ...
14 CitationsSource
#1Masatoshi Kudo (Kindai University)H-Index: 116
#2Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 80
Last. Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
view all 22 authors...
Summary Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Methods This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not rec...
1,531 CitationsSource
#1Jennifer Gill (LSE: London School of Economics and Political Science)H-Index: 10
#2Andrei BaiceanuH-Index: 1
Last. Panos Kanavos (LSE: London School of Economics and Political Science)H-Index: 40
view all 8 authors...
Aim: To better understand the hepatocellular carcinoma (HCC) patient journey, we conducted a patient survey across 13 countries. Methods: The survey included closed- and open-ended questions developed using an iterative process to gather information on demographics, diagnosis and treatment. Patients self-selected or were directed to the online survey by their doctor. Results: A total of 256 patients completed the survey. More than two-thirds (68%) felt they did not receive enough information abo...
15 CitationsSource
#1Käthe GoossenH-Index: 3
#2Solveig TenckhoffH-Index: 5
Last. Markus K. Diener (University Hospital Heidelberg)H-Index: 10
view all 7 authors...
Background The aim of the present study was to determine empirically which electronic databases contribute best to a literature search in surgical systematic reviews.
113 CitationsSource
Cited By0